Literature DB >> 19330008

Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation.

Edward S Morris1, Kelli P A MacDonald, Rachel D Kuns, Helen M Morris, Tatjana Banovic, Alistair L J Don, Vanessa Rowe, Yana A Wilson, Neil C Raffelt, Christian R Engwerda, Angela C Burman, Kate A Markey, Dale I Godfrey, Mark J Smyth, Geoffrey R Hill.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) is often used to hasten neutrophil recovery after allogeneic bone marrow transplantation (BMT), but the clinical and immunological consequences evoked remain unclear. We examined the effect of G-CSF administration after transplantation in mouse models and found that exposure to either standard G-CSF or pegylated-G-CSF soon after BMT substantially increased graft-versus-host disease (GVHD). This effect was dependent on total body irradiation (TBI) rendering host dendritic cells (DCs) responsive to G-CSF by upregulating their expression of the G-CSF receptor. Stimulation of host DCs by G-CSF subsequently unleashed a cascade of events characterized by donor natural killer T cell (NKT cell) activation, interferon-gamma secretion and CD40-dependent amplification of donor cytotoxic T lymphocyte function during the effector phase of GVHD. Crucially, the detrimental effects of G-CSF were only present when it was administered after TBI conditioning and at a time when residual host antigen presenting cells were still present, perhaps explaining the conflicting and somewhat controversial clinical studies from the large European and North American BMT registries. These data have major implications for the use of G-CSF in disease states where NKT cell activation may have effects on outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330008     DOI: 10.1038/nm.1948

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  30 in total

1.  Guidelines on the use of colony-stimulating factors in haematological malignancies.

Authors:  Antonio Pagliuca; Patrick A Carrington; Ruth Pettengell; Simoon Tule; Jane Keidan
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

Review 2.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation.

Authors:  G R Hill; J L Ferrara
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

3.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.

Authors:  G R Hill; J M Crawford; K R Cooke; Y S Brinson; L Pan; J L Ferrara
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

4.  CD1d-restricted NKT cells: an interstrain comparison.

Authors:  K J Hammond; D G Pellicci; L D Poulton; O V Naidenko; A A Scalzo; A G Baxter; D I Godfrey
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

5.  Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.

Authors:  G R Westerhof; R E Ploemacher; A Boudewijn; I Blokland; J H Dillingh; A T McGown; J A Hadfield; M J Dawson; J D Down
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

6.  Effect of KRN7000 on induced graft-vs-host disease.

Authors:  Shoshana Morecki; Soumya Panigrahi; Galina Pizov; Elena Yacovlev; Yael Gelfand; Osnat Eizik; Shimon Slavin
Journal:  Exp Hematol       Date:  2004-07       Impact factor: 3.084

7.  Donor APCs are required for maximal GVHD but not for GVL.

Authors:  Catherine C Matte; Jinli Liu; James Cormier; Britt E Anderson; Ioanna Athanasiadis; Dhanpat Jain; Jennifer McNiff; Warren D Shlomchik
Journal:  Nat Med       Date:  2004-08-01       Impact factor: 53.440

8.  Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Kelli P A MacDonald; Vanessa Rowe; Cheryl Filippich; Ranjeny Thomas; Andrew D Clouston; Joseph K Welply; Derek N J Hart; James L M Ferrara; Geoffrey R Hill
Journal:  Blood       Date:  2002-10-17       Impact factor: 22.113

9.  Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease.

Authors:  D Zeng; D Lewis; S Dejbakhsh-Jones; F Lan; M García-Ojeda; R Sibley; S Strober
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

10.  Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers.

Authors:  J L Matsuda; O V Naidenko; L Gapin; T Nakayama; M Taniguchi; C R Wang; Y Koezuka; M Kronenberg
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

View more
  24 in total

1.  Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis.

Authors:  Atsuo Okamura; Kimikazu Yakushijin; Yumiko Inui; Yohei Funakoshi; Yuriko Kawamori; Takanobu Shimada; Masanori Toyoda; Naoko Chayahara; Naomi Kiyota; Yutaka Fujiwara; Toru Mukohara; Hiroshi Matsuoka; Katsuya Yamamoto; Hironobu Minami
Journal:  Int J Hematol       Date:  2011-04-22       Impact factor: 2.490

2.  Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care.

Authors:  Olle Ringdén; Mats Remberger; Johan Törlén; Sigrun Finnbogadottir; Britt-Marie Svahn; Behnam Sadeghi
Journal:  Int J Hematol       Date:  2021-02-05       Impact factor: 2.490

3.  Choosing between GVHD and delayed engraftment.

Authors:  Paul J Martin
Journal:  Nat Med       Date:  2009-04       Impact factor: 53.440

Review 4.  G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept.

Authors:  U Deotare; G Al-Dawsari; S Couban; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

Review 5.  Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.

Authors:  Y S Jethava; S Sica; B Savani; F Socola; M Jagasia; M Mohty; A Nagler; A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2017-05-15       Impact factor: 5.483

Review 6.  Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.

Authors:  Mark A Exley; Lydia Lynch; Bindu Varghese; Michael Nowak; Nadia Alatrakchi; Steven P Balk
Journal:  Clin Immunol       Date:  2011-05-13       Impact factor: 3.969

7.  Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma.

Authors:  Xiaoru Sun; Lu Wang; Hongkai Li; Chuandi Jin; Yuanyuan Yu; Lei Hou; Xinhui Liu; Yifan Yu; Ran Yan; Fuzhong Xue
Journal:  Aging (Albany NY)       Date:  2021-06-16       Impact factor: 5.682

8.  Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease.

Authors:  Sam C Nalle; H Aimee Kwak; Karen L Edelblum; Nora E Joseph; Gurminder Singh; Galina F Khramtsova; Eric D Mortenson; Peter A Savage; Jerrold R Turner
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

Review 9.  Acute graft-versus-host disease: from the bench to the bedside.

Authors:  Gerard Socié; Bruce R Blazar
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

10.  A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.

Authors:  K Riesner; M Kalupa; Y Shi; S Elezkurtaj; O Penack
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.